Rocket Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Rocket Pharmaceuticals (RCKT).

Price Target Range — 13 Quarters

Analyst Consensus — 12 Analysts

8Buy

3Hold

1Sell

Consensus RatingBuy# Analysts12Avg. Consensus PT$9Upside to Avg. PT+250.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	Goldman Sachs	Richard Law	Upgrade	Sell→Neutral	$3→$4
Oct 7, 2026	Leerink Partners	Roanna Ruiz	PT Cut	Market Perform	$7→$4
Oct 7, 2026	Wedbush	Yun Zhong	Maintained	Outperform	$15
Oct 7, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$11
Sep 16, 2026	Wedbush	Yun Zhong	Maintained	Outperform	$15
Sep 16, 2026	Needham	Gil Blum	Upgrade	Hold→Buy	$9
Sep 15, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$11
Sep 1, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$11
Aug 11, 2026	Wedbush	Yun Zhong	PT Cut	Outperform	$16→$15
May 11, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$11
Mar 30, 2026	B of A Securities	Jason Zemansky	PT Raise	Buy	$8→$9
Mar 27, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$11
Mar 2, 2026	Goldman Sachs	Richard Law	PT Raise	Sell	$2→$3
Feb 27, 2026	Cantor Fitzgerald	Josh Schimmer	PT Raise	Overweight	$8→$10
Nov 18, 2025	B of A Securities	Jason Zemansky	PT Cut	Buy	$10→$8
Nov 18, 2025	JP Morgan	Tessa Romero	Downgrade	Overweight→Underweight	$261→$263
Oct 14, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$11
Oct 3, 2025	Leerink Partners	Mani Foroohar	PT Cut	Market Perform	$9→$7
Aug 20, 2025	B of A Securities	Jason Zemansky	Upgrade	Neutral→Buy	$4→$10
Aug 20, 2025	Chardan Capital	Geulah Livshits	Maintained	Buy	$11

Analyst Ratings News

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded Rocket Pharma, Generac, Palantir, Global Payments and Unity Software, with new or raised price targets.

Avi Kapoor

PRO
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

Goldman Sachs analyst Richard Law upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Sell to Neutral and raises the price target from $3 to $4.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

Leerink Partners analyst Roanna Ruiz maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the price target from $7 to $4.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.

Benzinga Newsdesk

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

Analysts upgraded SUNB, HAWK, and more, revising ratings and price targets.

Avi Kapoor

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.

Avi Kapoor

Rocket Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Rocket Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PRO
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

PRO
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

PRO
Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

Rocket Pharmaceuticals Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Rocket Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

PROGoldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

PROLeerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

PROWedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

This JB Hunt Transport Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

People Also Watch

People Also Watch

PRO
Goldman Sachs Upgrades Rocket Pharmaceuticals to Neutral, Raises Price Target to $4

PRO
Leerink Partners Maintains Market Perform on Rocket Pharmaceuticals, Lowers Price Target to $4

PRO
Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target